| Azelnidipine decreases plasma matrix metalloproteinase-9 levels after endovascular abdominal aortic aneurysm repair. | |
| | |
MedLine Citation:
|
PMID: 20103998 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We investigated the changes of matrix metalloproteinase (MMP) -9 in the peripheral blood samples of patients undergoing endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAAs), and the effect of azelnidipine on plasma MMP-9 levels in those patients. Levels of MMP-9 were measured in 22 patients who underwent EVAR for AAAs, and results were compared between a group receiving 16 mg azelnidipine daily (n=12) and a control group without azelnidipine (n=10). Measurements were taken preoperatively, and at 1 month and 3 months, postoperatively. Patients without endoleaks after EVAR showed a significant decrease in mean plasma MMP-9 levels (preoperative value: 39.5+/-14.3 ng/mL, after 1 month: 25.0+/-12.6, after 3 months: 28.2+/-10.2 ng/mL; P=0.004). In contrast, no significant decreases in mean plasma MMP-9 levels were observed in the patients with endoleaks after EVAR (preoperative value: 37.5+/-9.0 ng/mL, after 1 month: 26.8+/-8.4, after 3 months: 38.5+/-15.7 ng/mL; P=0.219). Moreover, among patients without endoleaks, those receiving azelnidipine showed a significantly greater decrease in the mean plasma MMP-9 levels for 3 months postoperatively (preoperative value: 47.7+/-13.2 ng/mL, after 1 month: 26.6+/-12.8, after 3 months: 26.1+/-11.4 ng/mL; P0.001) compared with the control group without endoleaks (preoperative value: 31.3+/-10.5 ng/mL, after 1 month: 33.4+/-12.1, after 3 months: 30.3+/-9.1 ng/mL; P=0.792). These results showed that azelnidipine treatment in patients without endoleak after EVAR was associated with a significant decrease in mean plasma MMP-9 levels for 3 months postoperatively. |
| | |
Authors:
|
Eiji Nakamura; Hidetoshi Akashi; Shinichi Hiromatsu; Atsuhisa Tanaka; Seiji Onitsuka; Shigeaki Aoyagi |
Related Documents
:
|
18503898 - Midterm outcomes of endovascular repair with the zenith endovascular graft: does the ip... 22950578 - Vascularization of myringo-/tympanoplastic grafts in active and inactive chronic mucosa... 17224498 - Long-term results of endovascular abdominal aortic aneurysm treatment with the first ge... 3267328 - Antifibrinolytic therapy in patients with aneurysmal subarachnoid haemorrhage. 12441448 - Ergonomics in a hospital and a university setting: the effect of worksite analysis on u... 21888858 - Hemoglobin level variability in hemodialysis patients treated with epoetin-β during 1 ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Kurume medical journal Volume: 56 ISSN: 1881-2090 ISO Abbreviation: Kurume Med J Publication Date: 2009 |
Date Detail:
|
Created Date: 2010-01-27 Completed Date: 2010-03-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 2985210R Medline TA: Kurume Med J Country: Japan |
Other Details:
|
Languages: eng Pagination: 25-32 Citation Subset: IM |
Affiliation:
|
Department of Surgery, Kurume University School of Medicine, Asahi-machi, Kurume, Japan. e0123@med.kurume-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aortic Aneurysm, Abdominal / enzymology, surgery* Azetidinecarboxylic Acid / analogs & derivatives*, pharmacology Blood Vessel Prosthesis Implantation* Calcium Channel Blockers / pharmacology* Dihydropyridines / pharmacology* Female Humans Male Matrix Metalloproteinase 9 / blood* Middle Aged |
| Chemical | |
Reg. No./Substance:
|
0/Calcium Channel Blockers; 0/Dihydropyridines; 123524-52-7/azelnidipine; 2517-04-6/Azetidinecarboxylic Acid; EC 3.4.24.35/Matrix Metalloproteinase 9 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of Short-term Exposure to Whole Body Vibration in Humans: Relationship between Wakefulness Le...
Next Document: Angiosarcoma of the breast with silicone granuloma: a case report.